Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer

2021 ◽  
pp. 1-9
Author(s):  
Renren Ouyang ◽  
Shiji Wu ◽  
Bo Zhang ◽  
Ting Wang ◽  
Botao Yin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cytokeratin 19 ◽  
Healthy Controls ◽  
Control Groups ◽  
Clinical Value ◽  
Tumor Associated Antigens ◽  
Pathological Subtype ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

BACKGROUND: This study aimed to investigate the efficiency of combining tumor-associated antigens (TAAs) and autoantibodies in the diagnosis of lung cancer. METHODS: The serum levels of TAAs and seven autoantibodies (7-AABs) were detected from patients with lung cancer, benign lung disease and healthy controls. The performance of a new panel by combing TAAs and 7-AABs was evaluated for the early diagnosis of lung cancer. RESULTS: The positive rate of 7-AABs was higher than the single detection of antibody. The positive rate of the combined detection of 7-AABs in lung cancer group (30.2%) was significantly higher than that of healthy controls (16.8%), but had no statistical difference compared with that of benign lung disease group (20.8%). The positive rate of 7-AABs showed a tendency to increase in lung cancer patients with higher tumor-node-metastasis (TNM) stages. For the pathological subtype analysis, the positive rate of 7-AABs was higher in patients with squamous cell carcinoma and small cell lung cancer than that of adenocarcinoma. The levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 211 (CYFRA 211) were significantly higher than that of benign lung disease and healthy control groups. An optimal model was established (including 7-AABs, CEA and CYFRA21-1) to distinguish lung cancer from control groups. The performance of this model was superior than that of single markers, with a sensitivity of 52.26% and specificity of 77.46% in the training group. Further assessment was studied in another validation group, with a sensitivity of 44.02% and specificity of 83%. CONCLUSIONS: The diagnostic performance was enhanced by combining 7-AABs, CEA and CYFRA21-1, which has critical value for the screening and early detection of lung cancer.

scholarly journals Diagnostic Value of HSP90α and Related Markers in Lung Cancer

2021 ◽  
Author(s):  
zhimin yuan ◽  
longhao wang ◽  
songlin hong ◽  
lin li ◽  
ting tang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Carcinoma ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Type ◽  
Clinical Value ◽  
Early Screening ◽  
Combined Application ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract PurposeTo investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer and the clinical value of HSP90α and other related markers in the diagnosis of lung cancer.MethodsThe plasma levels of HSP90α and related markers (CEA, NSE, CF211 and ProGRP) were detected in the blood of 560 patients with lung cancer by ELISA (enzyme-linked immunosorbent assay). Groups were divided according to the gender (male/female), age (age≤40, 41<age≤50, 51<age≤60, 61<age≤70 and age>70), types of lung cancer (small-cell, squamous carcinoma, adenocarcinoma, hybrid and other type), staging (Ⅰ, Ⅱ, Ⅲ and Ⅳ) and metastasis (metastasis and non-metastasis) separately. Wilcoxon Mann-Whitney test and Kruskal-Wallis test were used to compare statistical differences between two groups/among the multiple groups for each factor of HSP90α.ResultsNo statistical difference was found in plasma level of HSP90α among different age and gender groups (P> 0.05). In the group divided by lung cancer type, staging and metastasis status, there were statistical differences among different groups in HSP90α level (P< 0.05). R values of HSP90α correlated with other related markers in the diagnosis of lung cancer (P< 0.05). Although HSP90α and other related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it was statistically differences in the diagnostic positive rate between HSP90α and each marker (P< 0.01). Reduced cut-off value of HSP90α in lung cancer can effectively improve the positive rate of diagnosis when combined with other tumor biomarkers.ConclusionsHSP90α has significant clinical value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

scholarly journals Diagnostic value of HSP90α and Related Markers in Lung Cancer

2019 ◽  
Author(s):  
Zhimin Yuan ◽  
Songlin Hong ◽  
Lin Li ◽  
Lin He ◽  
Peng Xiao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Age Groups ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Type ◽  
Clinical Value ◽  
Early Screening ◽  
Significant Difference ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract Aims To prove the expression of heat shock protein 90α (HSP90α) in the lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α between the patients group and the healthy group in patients' age, gender, different pathological types, lung cancer staging, and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results The results showed no statistical difference in HSP90α among different age groups. And the HSP90α level cannot be distinguished by genders significantly (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer group and the squamous cell carcinoma group (P<0.05); In the group by stage, the HSP90α level of high staging was significantly higher than that low staging (P<0.05), and the significant difference among the groups; the HSP90α level at I/II/III/IV shows statistical differences among the groups (P<0.05); And the test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). While HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, there were statistically differences in the diagnostic positive rate between HSP90α and each maker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

scholarly journals Diagnostic value of HSP90α and Related Markers in Lung Cancer

2019 ◽  
Author(s):  
Zhimin Yuan ◽  
Songlin Hong ◽  
Lin Li ◽  
Lin He ◽  
Peng Xiao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Carcinoma ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Type ◽  
Clinical Value ◽  
Early Screening ◽  
Significant Difference ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

scholarly journals Diagnostic value of HSP90α and Related Markers in Lung Cancer

2019 ◽  
Author(s):  
Zhimin Yuan ◽  
Songlin Hong ◽  
Lin Li ◽  
Lin He ◽  
Peng Xiao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Carcinoma ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Type ◽  
Clinical Value ◽  
Early Screening ◽  
Significant Difference ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

scholarly journals Diagnostic value of HSP90α and Related Markers in Lung Cancer

2019 ◽  
Author(s):  
Zhimin Yuan ◽  
Songlin Hong ◽  
Lin Li ◽  
Lin He ◽  
Peng Xiao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Carcinoma ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Type ◽  
Clinical Value ◽  
Early Screening ◽  
Significant Difference ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

scholarly journals Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease

2019 ◽  
Vol 47 (7) ◽  
pp. 3344-3353
Author(s):  
Ning Li ◽  
Haisheng Hu ◽  
Ge Wu ◽  
Baoqing Sun
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Serum Levels ◽  
Scaling Analysis ◽  
Healthy Controls ◽  
Healthy Individuals ◽  
Reactive Protein ◽  
Increased Risk ◽  
Immune Factors

Objective Patients with interstitial lung disease (ILD) are at increased risk of developing lung cancer. We aimed to investigate the clinical significance of serum immune factors in this progression. Methods We retrospectively screened a hospital database from January 2012 to December 2016 for patients with lung cancer and ILD. We measured serum levels of C3, C4, IgA, IgG, IgM, C-reactive protein (CRP), ceruloplasmin (CER), and rheumatoid factor in these patients and in healthy controls. Results We analyzed data for 262 patients with lung cancer, 220 with ILD, and 57 healthy controls. CER levels were significantly higher in patients with lung cancer (0.35 ± 0.10 g/L) compared with both ILD patients (0.31 ± 0.25 g/L) and healthy individuals (0.25 ± 0.04 g/L). C3 and C4 levels were both significantly higher in healthy individuals compared with patients with lung cancer (C3: 1.70 ± 0.29 vs 1.04 ± 0.26 g/L, C4: 0.27 ± 0.24 vs 0.24 ± 0.09 g/L) and ILD (C3: 1.70 ± 0.29 vs 0.97 ± 0.25 g/L, C4: 0.27 ± 0.24 vs 0.21 ± 0.09 g/L). Optimal scaling analysis demonstrated that lung cancer was closely associated with CRP, CER, C3, and C4. Conclusions Increased levels of CRP and CER and decreased levels of C3 and C4 may identify patients with ILD at high risk of developing lung cancer.

scholarly journals Meta-markers for the differential diagnosis of lung cancer and lung disease

2016 ◽  
Vol 148 ◽  
pp. 36-43 ◽  
Author(s):  
Yong-In Kim ◽  
Jung-Mo Ahn ◽  
Hye-Jin Sung ◽  
Sang-Su Na ◽  
Jaesung Hwang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Differential Diagnosis ◽  
Lung Disease ◽  
Diagnosis Of Lung Cancer

scholarly journals Clinical Significance and Prognostic Value of Serum Dickkopf-1 Concentrations in Patients with Lung Cancer

2009 ◽  
Vol 55 (9) ◽  
pp. 1656-1664 ◽  
Author(s):  
Shi L e Sheng ◽  
Gang Huang ◽  
Bin Yu ◽  
Wen Xin Qin
Keyword(s):  
Lung Cancer ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Cytokeratin 19 ◽  
Healthy Controls ◽  
Serum Concentrations ◽  
Small Cell Lung ◽  
Increased Sensitivity ◽  
Cytokeratin 19 Fragment ◽  
Dickkopf 1

Abstract Background: Dickkopf-1 (DKK1), a secreted protein, is known as a negative regulator of the Wnt signaling pathway, which has been implicated in the development of several types of cancers. Clinical significance of serum DKK1 in lung cancer remains to be determined. Methods: A novel time-resolved immunofluorometric assay was developed. By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls. Serum cytokeratin 19 fragment and neuron-specific enolase values were obtained. Results: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls. Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls. Application of both DKK1 and cytokeratin 19 fragment increased sensitivity, correctly identifying 89.6% of the non–small cell lung cancer patients as positive. The use of both DKK1 and neuron-specific enolase increased sensitivity to detect small cell lung cancer to 86.2%. DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex. Patients with a DKK1 concentration of 22.6 μg/L or higher had a statistically significantly diminished survival compared with patients whose DKK1 values were lower. Conclusions: DKK1 was preferentially expressed in lung cancer. Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .

scholarly journals Values of different specimen preparation methods for the diagnosis of lung cancer by endobronchial ultrasound guided transbronchial needle aspiration

2019 ◽  
Author(s):  
YouZu Xu ◽  
Jian Lin ◽  
meifang chen ◽  
HaiHong Zheng ◽  
JiaXi Feng
Keyword(s):  
Lung Cancer ◽  
Needle Aspiration ◽  
Endobronchial Ultrasound ◽  
Ultrasound Guided ◽  
Transbronchial Needle Aspiration ◽  
Hilar Lymph Node ◽  
Treatment Type ◽  
Significant Difference ◽  
Positive Rate ◽  
Diagnosis Of Lung Cancer

Abstract Background: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has been become an important procedure for the diagnosis and staging of lung cancer. Our research identified the effects of different pathological preparation on the diagnosis of lung cancer for specimens obtained by biopsy. Methods: Patients were clinically considered if lung cancer was accompanied by mediastinal or hilar lymph node enlargement between March 2014 and November 2017. Specimens obtained by EBUS-TBNA were treated by three methods: traditional smear cytology, liquid-based cytology (LBC) and histopathology. Results: Of a total of 154 puncture sites from 153 patients, the total positive rate of combination for the three pathological treatment types (histopathology, direct traditional smear, and LBC) was 77.3%. The diagnostic positive rate for histopathology was 68.6%, direct traditional smear was 65.6%, and LBC was 60.4%; there was no significant differences among the three single pathological treatment types (P=0.29), but there was a statistically significant difference between the combination of three treatments and any single pathological treatment type (P=0.01). The diagnostic sensitivities of histopathology combined with traditional smear and histopathology combined LBC were 94.4% and 92.8%, respectively, the specificities and PPVs were both 100%, and the diagnostic accuracies were 95.5% and 94.2%, respectively; the sensitivities, specificities and diagnostic accuracies above were all higher than those of single specimen treatment and lower than those of the three combined. Conclusion: When EBUS-TBNA is used for the diagnosis and staging of lung cancer, the use of histopathological sections combined with direct cytological smear should be sufficient and is the most economical choice.

Sign in / Sign up

Export Citation Format

Share Document